Novo Nordisk considers flexible pricing for Wegovy
Novo Nordisk has no plans to lower the price of its weight loss drug Wegovy, but CEO Lars Fruergaard Jørgensen suggests the company will look to offer countries ”buy now, pay later” options to increase access to the treatment.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.